Business Context and Reporting Period
Company: ImmuCell Corporation (ICCC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: ImmuCell develops, manufactures, and sells products for the dairy and beef industries. Its primary revenue-generating product is First Defense (a vaccine for bovine enteritis). The company is heavily focused on the internal development of MastOut, a Nisin-based treatment for mastitis in dairy cows, which requires significant capital investment and FDA approval.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenues | $2,391,393 | $2,462,834 |
| Product Sales | $2,389,419 | $2,460,907 |
| Gross Margin (Product Sales) | $1,357,774 (57%) | $1,208,384 (49%) |
| Net Operating Loss | $(120,055) | $(388,252) |
| Net Loss | $(59,705) | $(182,449) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.06) |
| Cash and Cash Equivalents | $1,744,749 | $1,092,994 (Ending Q1 2009) |
| Short-Term Investments | $2,472,000 | $3,610,000 (Dec 31, 2009) |
| Total Current Assets | $6,289,951 | $6,306,728 (Dec 31, 2009) |
| Total Current Liabilities | $328,399 | $362,770 (Dec 31, 2009) |
| Net Cash Used in Operating Activities | $(274,566) | $(232,944) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 3% ($71,000) compared to the prior six-month period. While domestic sales increased by 8%, foreign sales dropped significantly by 33% ($221,000).
- Improved Profitability: The net loss narrowed substantially from $(182,449) in the prior year period to $(59,705). This improvement was driven by a significant reduction in product development expenses (down 20% to $738,782) and an increase in gross margin percentage from 49% to 57%.
- Expense Management: Product development expenses decreased by $183,000, reflecting the completion of the pivotal effectiveness study for MastOut in September 2009. Sales and marketing expenses increased by 31% ($66,000) due to strategic hiring.
- Liquidity Position: Cash and cash equivalents increased to $1.74 million, while short-term investments decreased to $2.47 million. Total liquid assets (cash + short-term investments) decreased slightly from $4.59 million at year-end 2009 to $4.22 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- MastOut Development: The company is committed to completing the development of MastOut. Key milestones include submitting the Chemistry, Manufacturing, and Controls (CMC) Technical Section to the FDA in Q4 2010 and the administrative New Animal Drug Application (NADA) by the end of 2011. A test market launch is targeted for late 2011, with full commercial launch in 2012.
- Financial Projections: Management projects continued net losses for the remainder of 2010 and throughout 2011 due to development costs. A return to profitability is expected in 2012, contingent on the success of MastOut or sustained sales of existing products.
- Financing: In August 2010 (subsequent to the period end), the company secured credit facilities totaling up to $2.1 million from TD Bank, N.A., including a $1 million mortgage (funds received), a $600,000 loan, and a $500,000 line of credit.
Risks and Contingencies
- Regulatory Approval: Commercialization of MastOut is not assured. The FDA must approve the NADA, specifically the "zero milk discard" claim, which is a key competitive advantage. European regulators are unlikely to approve a zero discard claim.
- Market Conditions: The U.S. dairy industry faces economic pressure from low milk prices and high feed costs, which may impact customer spending. Foreign sales volatility remains a risk.
- Customer Concentration: Three distributors accounted for 48% of product sales in the first six months of 2010 and 45% of trade accounts receivable.
- Capital Requirements: While current resources and new debt are sufficient for development through 2011, additional financing (likely from a partner) will be required for the commercial launch of MastOut in 2012.
Investor Verification Checklist
- Debt Covenants: Review the terms of the new $2.1 million credit facility with TD Bank, N.A., specifically regarding collateral (substantially all assets) and repayment schedules.
- CMC Submission Timeline: Verify the company's ability to submit the CMC Technical Section to the FDA in Q4 2010 as planned, as this is the critical path to approval.
- Foreign Sales Recovery: Monitor the trend in international sales, which declined 33% year-over-year, to assess if this is a temporary fluctuation or a structural loss of market share.
- Capital Runway: Confirm that the combination of cash, gross margins, and the new debt facility is sufficient to fund operations through the projected losses of 2011 without dilutive equity raises.
- Related Party Transactions: Note that a Board member controls a distributor (Stearns Veterinary Outlet) that purchased $142,000 of products in the six-month period.